The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair ...

Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the ...

Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...

The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest ...

Led by former Seagen CEO David Epstein, the startup claims it has a drug that could stand out from other PD1- and ...

An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple ...

The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a ...

While the pharma is still developing a MorphoSys drug acquired in its $2.9 billion deal for the biotech, it is closing down sites in the U.S. and Germany.

An experimental drug for Parkinson’s disease that Roche has been developing for more than a decade just flunked another key ...

Dec. 21, 2024 – Dec. 31, 2024 • New York, NY, USA, New York ...